Who is sponsoring NCT03545711?

NCT03545711 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT03545711?

Interventions in NCT03545711: Anlotinib Hydrochloride with Irinotecan.

What condition does NCT03545711 study?

NCT03545711 studies Colo-rectal Cancer.

Is NCT03545711 still recruiting?

NCT03545711 is currently status unknown. Last updated 6 August 2018.

Last reviewed 2018-08-06 · How we verify

NCT03545711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer

Status unknown Phase 1, PHASE2 Last updated 6 August 2018

What this trial tests

Phase 1, PHASE2 trial testing Anlotinib Hydrochloride with Irinotecan in Colo-rectal Cancer in 42 participants. Status unknown.

Timeline

26 May 2018

Primary endpoint
24 November 2019

24 November 2020

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	26 May 2018
Primary completion	24 November 2019
Estimated completion	24 November 2020
Sites	1 location across China

Drugs / interventions tested

Anlotinib Hydrochloride with Irinotecan — full drug profile →

Conditions studied

Colo-rectal Cancer — all drugs for Colo-rectal Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 70, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of this prospective non-randomised study in an escalated dose cohort. The primary endpoint of the dose-escalation phase is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of anlotinib when given in combination with irinotecan. The phase II (dose-expansion) portion is designed to characterize the safety and potential efficacy of the combination therapy in pretreated advanced colorectal cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anlotinib as a molecular targeted therapy for tumors.
Gao Y, Liu P, Shi R. · · 2020 · cited 108× · PMID 32724339 · DOI 10.3892/ol.2020.11685

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
NCT06880055 — Shield Post-Approval Study Protocol · recruiting
NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03545711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 6 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03545711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing